325 East Middlefield Road
4 articles with IGM Bioscences
GM Bioscences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors.
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology Expert, to Lead Company's Emerging Clinical Development Initiatives